Systemic changes of tryptophan catabolites via the indoleamine-2,3- dioxygenase pathway in primary cervical cancer

Anticancer Research

Volumn 31, Issue 8, 2011, Pages 2629-2635

  Fotopoulou, Christina ^a   Sehouli, Jalid ^a   Pschowski, Rene ^a   Von Haehling, Stephan ^a   Domanska, Grazyna ^b   Braicu, Elena Ioana ^a   Fusch, Gerhard ^b   Reinke, Petra ^a   Schefold, Joerg C ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Cervical cancer; Immunomodulation; Indoleamine 2,3 dioxygenase; Kynurenic acid; Quinolinic acid

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; KYNURENIC ACID; KYNURENINE; QUINOLINIC ACID; SEROTONIN; TRYPTOPHAN;

ABDOMINAL SURGERY; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER STAGING; CATABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; PATIENT IDENTIFICATION; PRIMARY TUMOR; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; UTERINE CERVIX CANCER;

ADULT; AGED; FEMALE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MIDDLE AGED; TRYPTOPHAN; UTERINE CERVICAL NEOPLASMS;

EID: 79961204624     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Takikawa O, Yoshida R, Kido R and Hayaishi O: Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase. J Biol Chem 261: 3648-3653, 1986. (Pubitemid 17200663)
2. Ino K, Yoshida N, Kajiyama H, Shibata K, Yamamoto E, Kidokoro K, Takahashi N, Terauchi M, Nawa A, Nomura S, Nagasaka T, Takikawa O and Kikkawa F: Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer 95: 1555-1561, 2006. (Pubitemid 44863359)
3. Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N, Boon T and Van den Eynde BJ: Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9: 1269-1274, 2003.
4. Murr C, Widner B, Sperner-Unterweger B, Ledochowski M, Schubert C and Fuchs D: Immune reaction links disease progression in cancer patients with depression. Med Hypotheses 55: 137-140, 2000. (Pubitemid 30612102)
5. Huang A, Fuchs D, Widner B, Glover C, Henderson DC and Allen-Mersh TG: Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer 86: 1691-1696, 2002. (Pubitemid 34712909)
6. Liu X, Newton RC, Friedman SM and Scherle PA: Indoleamine 2,3-dioxygenase, an emerging target for anti cancer therapy. Curr Cancer Drug Targets 9: 938-952, 2009.
7. Okamoto A, Nikaido T, Ochiai K, Takakura S, Saito M, Aoki Y, Ishii N, Yanaihara N, Yamada K, Takikawa O, Kawaguchi R, Isonishi S, Tanaka T and Urashima M: Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 11(16): 6030-6039, 2005. (Pubitemid 41170335)
8. Takao M, Okamoto A, Nikaido T, Urashima M, Takakura S, Saito M, Saito M, Okamoto S, Takikawa O, Sasaki H, Yasuda M, Ochiai K and Tanaka T: Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of ovarian cancer. Oncol Rep 17(6): 1333-1339, 2007.
9. Leung BS, Stout LE, Shaskan EG and Thompson RM: Differential induction of indoleamine-2,3-dioxygenase (IDO) by interferon-gamma in human gynecologic cancer cells. Cancer Lett 66(1): 77-81, 1992.
10. Nelson BH: IDO and outcomes in ovarian cancer. Gynecol Oncol 115: 179-180, 2009.
11. International Federation of Gynecology and Obstetrics: Changing in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 156: 263-264, 1987.
12. Friberg M, Jennings R, Alsarraj M, Dessureault S, Cantor A, Extermann M, Mellor AL, Munn DH and Antonia SJ: Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T-cell-mediated rejection. Int J Cancer 101: 151-155, 2002. (Pubitemid 34970907)
13. Astigiano S, Morandi B, Costa R, Mastracci L, D'Agostino A, Ratto GB, Melioli G and Frumento G: Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non small cell lung cancer. Neoplasia 7: 390-396, 2003.
14. Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, Messina JL, Chandler P, Koni PA and Mellor AL: Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 114: 280-290, 2004. (Pubitemid 39071633)
15. Lob S and Konigsrainer A: Is IDO a key enzyme bridging the gap between tumor escape and tolerance induction? Langenbecks Arch Surg 393(6): 995-1003, 2008.
16. Inaba T, Ino K, Kajiyama H, Yamamoto E, Shibata K, Nawa A, Nagasaka T, Akimoto H, Takikawa O and Kikkawa F: Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma. Gynecol Oncol 115(2): 179-180, 2009.
17. Ino K, Yamamoto E, Shibata K, Kajiyama H, Yoshida N, Terauchi M et al: Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumorinfiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. Clin Cancer Res 14(8): 2310-2317, 2008. (Pubitemid 351551062)
18. Gao YF, Peng RQ, Li J, Ding Y, Zhang X, Wu XJ, Pan ZZ, Wan DS, Zeng YX and Zhang XS: The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer. J Transl Med 7: 71, 2009.
19. Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, Werner ER, Werner-Felmayer G, Weiss HG, Göbel G, Margreiter R, Königsrainer A, Fuchs D and Amberger A: Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T-cells. Clin Cancer Res 12(4): 1144-1151, 2006. (Pubitemid 43342502)
20. Liu J, Lu G, Tang F, Liu Y and Cui G: Localization of indoleamine 2,3-dioxygenase in human esophageal squamous cell carcinomas. Virchows Arch 455(5): 441-448, 2009.
21. Batista CE, Juhász C, Muzik O, Kupsky WJ, Barger G, Chugani HT, Mittal S, Sood S, Chakraborty PK and Chugani DC: Imaging correlates of differential expression of indoleamine 2,3-dioxygenase in human brain tumors. Mol Imaging Biol 11(6): 460-466, 2009.
22. Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N, Boon T and Van den Eynde BJ: Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9: 1269-1274, 2003.
23. Sedlmayr P, Semlitsch M, Gebru G, Karpf E, Reich O, Tang T, Wintersteiger R, Takikawa O and Dohr G: Expression of indoleamine 2,3-dioxygenase in carcinoma of human endometrium and uterine cervix. Adv Exp Med Biol 527: 91-95, 2003. (Pubitemid 38197632)
24. Nakamura T, Shima T, Saeki A, Hidaka T, Nakashima A, Takikawa O and Saito S: Expression of indoleamine-2,3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer Sci 98: 874-881, 2007. (Pubitemid 46691826)